Climb Bio, Inc. has made significant advancements in its clinical research by announcing additional Phase 1 data for its monoclonal antibody CLYM116, which targets IgA nephropathy. This announcement was made in conjunction with Beijing Mabworks Biotech Co., Ltd. during the American Society of Nephrology (ASN) Kidney Week 2026, held from October 21-25 in Denver, Colorado. The results presented are expected to enhance the company's position in the pharmaceutical preparations sector.
Background
Climb Bio, Inc. is a pharmaceutical company focused on developing innovative therapies for kidney diseases. The company is classified under the Standard Industrial Classification (SIC) code 2834, which pertains to Pharmaceutical Preparations. Climb Bio trades on the Nasdaq under the ticker symbol CLYM. The company was previously known as Eliem Therapeutics, Inc. until a name change in February 2019.
What the Filing Says
The SEC filing details that on October 23, 2026, Climb Bio and Mabworks released a press statement regarding the results of additional Phase 1 data for CLYM116, an anti-APRIL monoclonal antibody. This data was presented at ASN Kidney Week 2026. The filing states, "These data were presented at the American Society of Nephrology (ASN) Kidney Week 2026, which is taking place October 21-25, 2026, in Denver, Colorado." The filing also includes a copy of the press release as Exhibit 99.1.
Impact
The results from the Phase 1 trials may significantly influence the treatment landscape for IgA nephropathy, a kidney disorder that affects many patients worldwide. The data indicates that CLYM116 has a prolonged half-life and shows promise for deep and durable APRIL suppression, which is crucial for managing this condition. The findings could affect healthcare providers, patients, and stakeholders in the pharmaceutical industry, particularly those focused on kidney disease treatments.
What's Next
Climb Bio is continuing its Phase 1 clinical trials in both Australia and China, which are randomized, double-blind, placebo-controlled studies designed to further evaluate the safety and efficacy of CLYM116. The filing does not specify any immediate next steps following the announcement of the data.